Exploratory study of humoral and cellular immunity to 17DD Yellow Fever vaccination in children and adults residents of areas without circulation of Yellow Fever Virus. Issue 5 (31st January 2022)

• Record Type: Journal Article
• Authors: Reis, Laise Rodrigues; Costa-Rocha, Ismael Artur da; Campi-Azevedo, Ana Carolina; Peruhype-Magalhães, Vanessa; Coelho-dos-Reis, Jordana Grazziela; Costa-Pereira, Christiane; Otta, Dayane Andriotti; Freire, Larissa Chaves; Lima, Sheila Maria Barbosa de; Azevedo, Adriana de Souza; Schwarcz, Waleska Dias; Ano Bom, Ana Paula Dinis; Silva, Andrea Marques Vieira da; Souza, Alessandro Fonseca de; Castro, Thalita da Matta de; Ferroco, Clara Lucy de Vasconcellos; Filippis, Ana Maria Bispo de; Nogueira, Fernanda de Bruycker; Homma, Akira; Domingues, Carla Magda; Sousa, Eduardo Sérgio Soares; Camacho, Luiz Antônio Bastos; Maia, Maria de Lourdes de Souza; Teixeira-Carvalho, Andréa; Martins-Filho, Olindo Assis
• Is Part Of: Vaccine. Volume 40:Issue 5(2022)
• Page Start: 798
• Page End: 810
• Publication Date: 2022-01-31
• Subjects: Yellow Fever -- 17DD vaccine -- Neutralizing antibodies -- Cellular memory -- Children -- Adults; Vaccines -- Periodicals; 615.372
• DOI: 10.1016/j.vaccine.2021.12.029
• Languages: English
• ISSNs: 0264-410X

Abstract

Abstract: The present investigation comprised two independent observational arms to evaluate the influence of pre-existing flavivirus humoral immunity and the age-impact on 17DD-YF vaccination immunity. Flavivirus (YFV; DENV; ZIKV) serology and YF-specific cellular immunity was evaluated in 288 children/9 Mths –4 Yrs and 288 adults/18–49 Yrs residents of areas without YFV circulation. Data demonstrated that flavivirus seropositivity at baseline was higher in Adults as compared to Children (26%;87%;67% vs 6%;13%;15%, respectively). The heterologous flavivirus seropositivity (DENV; ZIKV) did not impact the YF-specific cellular immune response at baseline. However, higher levels of NCD4, EMCD8, IFN-MCD8, NCD19 and nCMCD19 were observed in subjects with pre-existing YFV seropositivity. Primary vaccination of YFV-seronegative volunteers led to higher levels of YF-neutralizing antibodies in Adults as compared to Younger Children (9 Mths –2 Yrs ). Although similar seropositivity rates observed amongst Children and Adults at D30-45, lower rates were observed in Younger Children (9 Mths –2 Yrs ) at D365 (94%;95%;100% vs 87%;96%;99%, respectively). A progressive decline in antibody levels were reported at D365, being more expressive in Children as compared to Adults. All age-subgroups exhibited at D30-45 increased levels of eEfCD4, EMCD4, IFN-MCD8 and nCMCD19 together with a decrease of eEfCD8 and CMCD8. While an increase of EMCD8 were observed in all subgroups at D30-45, a declined duration at D365 was reported only in Younger Children (9 Mths –2 Yrs ). Biomarker signatures further support that only Younger Children (9 Mths –2 Yrs ) presented a progressive decline of EMCD8 at D365. Together, these findings demonstrated that regardless the similarities observed in YF-neutralizing antibodies, the age impacts the duration of cellular immune response to primary 17DD-YF vaccination.